FDA revises labeling of Biogen's Alzheimer's drug to emphasize early treatment

[cafead]

via The Food and Drug Administration, under heavy criticism over its decision last month to approve Biogen's Alzheimer's drug Aduhelm, has revised the medicine's prescribing information in an effort to focus treatment to the type of patients who were included in clinical testing.

article source